Upper Tract Urothelial Carcinoma
Research activity is centered on upper tract urothelial carcinoma, also known as upper urinary tract transitional cell carcinoma, with attention to treatment pathways for patients undergoing surgical management. The clinical focus includes the role of cisplatin-based chemotherapy in relation to disease control.
- Neoadjuvant chemotherapy
- Adjuvant chemotherapy
- Cisplatin-based treatment
Interest extends to how systemic therapy is integrated around surgery in this uro-oncology setting.
Renal Function and Treatment Eligibility
The sponsor supports research on renal function assessment in patients with UTUC, with emphasis on identifying those who are fit to receive platinum-based therapy. This includes evaluation of treatment eligibility in a population where kidney function can limit access to standard systemic therapy.
- Kidney function assessment
- Platinum eligibility
- Patient fitness for chemotherapy
These interests reflect the clinical importance of selecting patients who can safely receive cisplatin in the perioperative setting.
Perioperative Systemic Therapy
Clinical research activity includes the use of chemotherapy before or after surgery in upper urinary tract cancer. The therapeutic domain covers sequencing of systemic treatment relative to surgical intervention and the practical delivery of planned chemotherapy.
- Pre-surgical treatment
- Post-surgical treatment
- Surgical oncology
There is particular interest in the management of patients who require coordinated multimodal cancer care.
Treatment Feasibility and Completion
The funded trial landscape examines whether patients can begin and complete planned chemotherapy in routine clinical conditions. This includes attention to treatment feasibility, continuity of care, and the ability to deliver intended therapy in full.
- Chemotherapy completion
- Treatment feasibility
- Therapy delivery
These topics are especially relevant for patients with urothelial malignancy requiring carefully timed systemic treatment.
